Subject characteristics at time of enrolment
| Mean (SD), median (range) or n (%) | All infants (n=100) | V4 algorithm (n=50) | V5 algorithm (n=50) | Blood gas analysis cohort (n=57) |
| Gestational age (completed weeks) | 34 (4) | 35 (5) | 34 (4) | 35 (4) |
| Corrected gestational age (completed weeks) | 36 (4) | 36 (4) | 36 (4) | 36 (4) |
| Postnatal age (days) | 4 (0, 84) | 4 (1, 38) | 4 (0, 84) | 3 (0, 42) |
| Birth weight (g) | 2483 (985) | 2661 (1028) | 2305 (915) | 2728 (964) |
| Weight at study (g) | 2630 (958) | 2743 (1073) | 2517 (823) | 2830 (948) |
| Gender, female | 44 (44%) | 23 (46%) | 21 (42%) | 26 (46%) |
|
Reason for mechanical ventilation (number) Primary respiratory disease: pneumonia (4), CLD (2), evolving CLD (3), MAS (4), RDS (22), prematurity (3), pneumothorax (1), RSV bronchiolitis (2), Pierre Robin syndrome (3), bilateral vocal cord palsy (1), TOF/OA (7), PDA (2), bilateral chylothoraces (1); shock/cardiac: sepsis (3), postoperative cardiac (2), metabolic acidosis (1); postoperative support of respiratory drive: laparotomy (15), choanal atresia repair (1), gastroschisis (8), NEC/peritonitis (3), myelomeningocele (1); other respiratory drive support: HIE (8), hypotonia (1), seizures (1) and renal failure (1). | ||||
|
Relevant mediations at time of study (all infants) Opiate infusion (48), opiate+midazolam infusion (38), nidazolam infusion (2), one or more inotrope (31) | ||||
Relevant medications prior to study (all infants).
Surfactant (30), antenatal corticosteroids (23), postnatal corticosteroids (12).
CLD, chronic lung disease; DORV, double outlet right ventricle; HIE, hypoxic ischaemic encephalopathy; MAS, meconium aspiration syndrome; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome; RSV, respiratory syncytial virus; TOF/OA, tracheo-oesophageal fistula/oesophageal atresia.